Short-term opioids for breathlessness in stable chronic heart failure: A randomized controlled trial

European Journal of Heart Failure

Volumn 13, Issue 9, 2011, Pages 1006-1012

  Oxberry, Stephen G ^a   Torgerson, David J ^a   Bland, J Martin ^a   Clark, Andrew L ^b   Cleland, John G F ^b   Johnson, Miriam J ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Analgesics; Cross over studies; Dyspnoea; Heart failure; Opioid; Palliative care; Randomized Controlled Trial

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOMPERIDONE; MORPHINE SULFATE; OXYCODONE; PLACEBO; SENNA EXTRACT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEADACHE; HEART FAILURE; HUMAN; LOW DRUG DOSE; MALE; NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATHOGENESIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECOMMENDED DRUG DOSE; SCORING SYSTEM; SHORT COURSE THERAPY; SIDE EFFECT; SWEATING; TREATMENT DURATION; UNITED KINGDOM; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MORPHINE; OXYCODONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 80052015409     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr068     Document Type: Article

References (37)

1. Murray SA, Boyd K, Kendall M, Worth A, Benton TF, Clausen H. Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the community. BMJ (Clinical research ed.) 2002;325:929.
2. Thomas S, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in the elderly. Clinics in geriatric medicine 2007;23:1-10.
3. Jennings AL, Davies AN, Higgins JP, Broadley K. Opioids for the palliation of breathlessness in terminal illness. Cochrane database of systematic reviews (Online), 2001: CD002066.
4. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003;327:523-528.
5. Johnson MJ, Oxberry SG, Cleland JGF, Clark AL. Measurement of breathlessness in clinical trials in patients with chronic heart failure: the need for a standardised approach: a systematic review. Eur J Heart Fail 2010;12:137-147.
6. Chua TP, Harrington D, Ponikowski P,Webb PK, Poole WPA, Coats AJ. Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 1997;29:147-152. (Pubitemid 27028732)
7. Williams SG, Wright DJ, Marshall P, Reese A, Tzeng B, Coats AJS, Tan L. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart 2003;89:1085-1086. (Pubitemid 37046855)
8. Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ. Morphine for the relief of breathlessness in patients with chronic heart failure-a pilot study. Eur J Heart Fail 2002;4:753-756. (Pubitemid 35403084)
9. Francis GS. Neuroendocrine activity in congestive heart failure. Am J Cardiol 1990; 66:33D-38D.
10. Fontana F, Bernardi P, Pich EM, Capelli M, Bortoluzzi L, Spampinato S, Canossa M. Relationship between plasma atrial natriuretic factor and opioid peptide levels in healthy subjects and in patients with acute congestive heart failure. Eur Heart J 1993;14:219-225. (Pubitemid 23089508)
11. Perna GP, Modoni S, Valle G, Stanislao M, Loperfido F. Plasma beta-endorphin response to exercise in patients with congestive heart failure. Chest 1997;111: 19-22. (Pubitemid 27043601)
12. Wong TM, Shan J. Modulation of sympathetic actions on the heart by opioid receptor stimulation. J Biomed Science 2001;8:299-306. (Pubitemid 32678935)
13. Pepe S, van den Brink OWV, Lakatta EG, Xiao RP. Cross-talk of opioid peptide receptor and beta-adrenergic receptor signalling in the heart. Cardiovasc Res 2004;63:414-422. (Pubitemid 38970185)
14. Chua TP, Clark AL, Amadi AA, Coats AJ. Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol 1996;27:650-657. (Pubitemid 26080387)
15. Piepoli M, Clark AL, Volterrani M, Adamopoulos S, Sleight P, Coats AJ. Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation 1996;93:940-952. (Pubitemid 26074831)
16. Rimoy GH, Bhaskar NK, Wright DM, Rubin PC. Mechanism of diuretic action of spiradoline U-62066E-a kappa opioid receptor agonist in the human. Br J Clin Pharmacol 1991;32:611-615.
17. SIGN. Management of Chronic Heart Failure: Guideline 95. 2007: Scottish Intercollegiate Guidelines Network, ISBN 1899893946.
18. Statutory Instrument No. 1031. The Medicines for Human Use (Clinical Trials) Regulations 2004. http://www.opsi.gov.uk/si/si2004/20041031.htm (7 May 2010).
19. Gift AG, Narsavage G. Validity of the numeric rating scale as a measure of dyspnea. Am J Crit Care 1998;7:200-204. (Pubitemid 128460535)
20. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessness in palliative care? A systematic review. Palliat Med 2007; 21:177-191. (Pubitemid 46958244)
21. Currow DC, Agar M, Smith J, Abernethy AP. Does palliative home oxygen improve dyspnoea? A consecutive cohort study. Palliat Med 2009;23:309-316.
22. Abernethy AP, McDonald C, Frith P, Clark K, Herndon JE, Marcello J, Young IH, Bull J, Wilcock A, Booth S, Wheeler JL, Tulsky JA, Crockett AJ, Currow DC. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnea: a double-blind, randomized controlled trial. Lancet 2010; 376:784-793.
23. Barton R, English A, Nabb S, Rigby AS, Johnson MJ. A randomised trial of high vs low intensity training in breathing techniques for breathless patients with malignant lung disease: a feasibility study. Lung Cancer 2010;70:313-319.
24. Bausewein C, Farquhar M, Booth S, Gysels M, Higginson IJ. Measurement of breathlessness in advanced disease: a systematic review. Respir Med 2007;101: 399-410. (Pubitemid 46205909)
25. Dorman S, Jolley C, Abernethy AP, Currow DC, Johnson M, Farquhar M, Griffiths G, Peel T, Moosavi SH, Byrne A, Wilcock A, Alloway L, Bausewein C, Higginson IJ, Booth S. Researching breathlessness in palliative care: consensus statement of the National Cancer Research Institute Palliative Care Breathlessness Subgroup. Palliat Med 2009;23:213-227.
26. Borg G. A category scale with ratio properties for intermodal and interindividual comparisons. In: Geissler HG, Petzoldt G, eds. Psychophysical Judgements and the Process of Perception. Berlin: Deutscher Verlag; 1982.
27. Guyatt GH, Feeny DH, Patrick DL. Measuring health related quality of life. Ann Intern Med 1993;118:622-629. (Pubitemid 23102698)
28. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984;53:2002-2007.
29. Ware JE, Konsinski M, Keller SD. SF-12: an even shorter health survey. Med Outcomes Trust Bull 1996;4:2.
30. Senn S. Crossover Trials in Clinical Research. 2nd ed. Chichester: John Wiley and Sons; 2002.
31. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. User's Manual for the SF-12v2 Health Survey with a Supplement Documenting the SF-12 survey 2002. Lincoln, R.I: QualityMetric Incorporated.
32. Karras DJ, Sammon ME, Terrigino CA, Lopez BL, Griswold SK, Arnold GK. Clinically meaningful changes in quantitative measures of asthma severity. Acad Emerg Med 2000;7:327-334. (Pubitemid 30207971)
33. Ander DS, Aisiku IP, Ratcliff JJ, Todd KH, Gotsch K. Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful? Congest Heart Fail 2004;10:188-191.
34. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale and Visual Analog Scale. COPD 2005;2:105-110. (Pubitemid 40776230)
35. Currow DC, McDonald C, Oaten S, Kenny B, Allcroft P, Frith P, Briffa M, Johnson MJ, Abernethy AP. Once daily opioids for chronic dyspnoea: a dose increment and pharmacovigilance study. J Pain Symptom Manage 2011. Published online doi: 10.1016/j.jpainsymman.2010.11.021.
36. Guyatt GH, Nogradi S, Halcrow S, Singer J, Sullivan MJJ, Fallen EL. Development and Testing of a New Measure of Health Status for Clinical Trials in Heart Failure. J Gen Intern Med 1989;4:101-107. (Pubitemid 19081188)
37. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;47:773-778. (Pubitemid 17142007)